NCT04909073View on ClinicalTrials.gov

Observational Study of Afatinib 30 mg Daily

RecruitingOBSERVATIONAL
Enrollment

69

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
Interventions
DRUG

Afatinib

Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.

Trial Locations (1)

Unknown

RECRUITING

Nationa University Hospital, Singapore

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

National University Hospital, Singapore

OTHER